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Objective. The intestinal inflammation observed
in patients with ankylosing spondylitis (AS) is charac-
terized by an overexpression of interleukin-23 (IL-23).
IL-23 is known to regulate IL-22 production through
lamina propria NKp44! natural killer (NK) cells,
which are thought to be involved in protective mucosal
mechanisms. This study was undertaken to evaluate the
frequency of NKp44! NK cells and the expression of
IL-22 in the ileum of AS patients.
Methods. Tissue NKp44! NK cells, NKp46! NK
cells, and IL-22–producing cells were analyzed by flow
cytometry. Quantitative gene expression analysis of
IL-22, IL-23, IL-17, STAT-3, and mucin 1 (MUC-1) was
performed by reverse transcriptase–polymerase chain
reaction on ileal samples from 15 patients with AS, 15
patients with Crohn’s disease (CD), and 15 healthy
controls. NKp44, pSTAT-3, and IL-22 expression was
analyzed by immunohistochemistry.
Results. The frequency of NKp44! but not
NKp46! NK cells was increased in the inflamed ileum
of AS patients compared to CD patients and controls.
The frequency of NKp46! NK cells was significantly
increased only in CD patients. Among CD4! lympho-
cytes and NKp44! NK cell subsets, the latter were the
major source of IL-22 on lamina propria mononuclear
cells from AS patients. Significant up-regulation of
IL-22, IL-23p19, MUC-1, and STAT-3 transcripts in the
terminal ileum of patients with AS was observed. Im-
munohistochemical analysis confirmed the increased
IL-22 and pSTAT-3 expression in inflamed mucosa from
AS and CD patients.
Conclusion. Our findings indicate that overex-
pression of IL-22, together with an increased number of
IL-22–producing NKp44! NK cells, occurs in the gut of
AS patients, where it appears to play a tissue-protective
role.
The asymptomatic ileal inflammation observed
in patients with ankylosing spondylitis (AS) is immuno-
logically characterized by the overexpression of
interleukin-23 (IL-23). This overexpression, however,
does not appear to be sufficient to induce Th17 polar-
ization (1). Protective immunologic mechanisms, such as
the expansion of IL-10–producing Treg cells, could, at
least in part, explain the absence of a clear Th17
response despite the high levels of IL-23 observed in AS
patients (2).
Although the primary focus of investigations of
IL-23 function has been its effect on the adaptive
immune system through the regulation of the Th17
pathway, recent studies of the gut suggest an important
role for IL-23 in regulating innate immune responses
(3–8). These studies have in fact identified a subset of
IL-23–responsive human lamina propria natural killer
(NK) cells that contribute to intestinal mucosa immu-
nity. Lamina propria NK cells comprise 2 main popula-
tions, interferon-! (IFN!)–producing NKp46! NK cells
and IL-22–producing NKp44! NK cells, which are
balanced in normal human intestinal mucosa (9). This
balance is disrupted in the inflamed mucosa of patients
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with Crohn’s disease (CD), where protective IL-22–
producing NKp44! NK cells are markedly reduced,
whereas pathogenic IFN!-producing NKp46! NK cells
are significantly expanded (9). Interestingly, the produc-
tion of IFN! and IL-22 by NKp46! and NKp44! NK
cells, respectively, appears to be highly dependent on
IL-23 signaling.
IL-22, released by NKp44! NK cells upon IL-23
signaling, could act by constraining inflammation and
protecting mucosal integrity. At mucosal sites, in fact,
IL-22 acting through STAT-3 signaling increases the
innate immune responses of tissue cells, protecting the
epithelial barrier in the gut through the induction of
goblet cell hyperplasia and mucin production (10,11),
and enhancing tissue regeneration.
In inflammatory bowel diseases, IL-22 seems to
play a local protective role in ulcerative colitis (10), and
a systemic protective role in CD (12). Conversely, IL-22
seems to act as a proinflammatory cytokine in certain
human T cell–mediated inflammatory diseases, such as
psoriasis (13) and rheumatoid arthritis (14), and also to
play a local pathogenic role in CD (15). Although it is
likely that this pathogenic effect could reflect dysregu-
lated duration of production and/or the concentration of
IL-22, the functional outcomes of IL-22 expression seem
to be governed by the coexpression of IL-17A. When
coexpressed, IL-17A and IL-22 may act synergistically to
promote chemokine expression, neutrophil recruitment,
and inflammation, whereas IL-22 in the absence of
IL-17A may promote essentially tissue-protective re-
sponses (16).
The aim of this study was to evaluate the expres-
sion of IL-22 at both the messenger RNA (mRNA) and
protein levels, and to characterize the cellular source of
IL-22 in the inflamed gut of AS patients. We also
evaluated IL-22–dependent intestinal tissue–protective
responses, such as epithelial expression of pSTAT-3,
goblet cell hyperplasia, and increased mucin content.
PATIENTS AND METHODS
Patients. Multiple ileal biopsy samples from patients
with AS without clinical symptoms of bowel inflammation,
patients with CD, and normal controls were consecutively
obtained. The demographic and clinical characteristics of the
patients and controls are summarized in Table 1. The AS
group consisted of 15 consecutive patients (10 men and 5
women), ages 20–48 years, who were diagnosed according to
the modified New York criteria (17). All of the AS patients
were HLA–B27 positive. Seven of the 15 AS patients were
receiving nonsteroidal antiinflammatory drugs at the time of
ileocolonoscopy. At the time mucosal biopsy specimens were
obtained, none of the AS patients had ever received biologic
treatment. The CD group consisted of 15 patients (9 men and
6 women) ages 18–50 years. At the time of sample collection,
none of the patients with CD were receiving corticosteroids,
immunosuppressants, or biologic agents. Biopsy specimens
were obtained from ileal zones of active ulceration. The
control group consisted of 15 normal subjects (12 men and 3
Table 1. Baseline characteristics of the patients*
AS patients with
acute inflammation
(n " 8)
AS patients with
chronic inflammation
(n " 7)
CD patients
(n " 15)
Age, years 35 (20–44) 38 (20–48) 46 (18–50)
Sex, no. (%) male 6 (75) 4 (57) 9 (60)
Disease duration, months 18 (14–32) 20 (12–26) 7 (2–14)
CRP, mg/liter 1 (0.4–2) 1 (0.2–2) 5 (3–14)†
Axial involvement, no. (%) 8 (100) 7 (100) NA
Peripheral arthritis, no. (%) 2 (25) 3 (43) NA
Enthesitis/dactylitis, no. (%) 2 (25) 1 (14) NA
Uveitis, no. (%) 0 (0) 1 (14) NA
Concomitant medical treatment, no. (%)
NSAIDs 4 (50) 3 (43) 0 (0)
Biologic agents 0 (0) 0 (0) 0 (0)
Immunosuppressants 0 (0) 0 (0) 0 (0)
CD Activity Index score‡ NA NA 245 (156–580)
BASDAI score§ 4.4 (4.2–6.6) 5 (4.2–7) NA
* Except where indicated otherwise, values are the median (range). The control group consisted of 15 healthy
controls (12 men) with a median age of 52 years (range 38–68 years). CRP " C-reactive protein; NA " not
applicable; NSAIDs " nonsteroidal antiinflammatory drugs.
† P # 0.0001 versus patients with ankylosing spondylitis (AS) with acute inflammation and patients with AS with
chronic inflammation.
‡ Scores for the Crohn’s disease (CD) Activity Index range from 0 to 600, with higher scores indicating more
severe disease.
§ Scores for the Bath AS Disease Activity Index (BASDAI) range from 0 to 10, with higher scores indicating
more severe disease.
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women), ages 38–68 years, who were undergoing ileocolonos-
copy for routine evaluation. Paired specimens for histologic
analysis, reverse transcriptase–polymerase chain reaction (RT-
PCR), and lamina propria mononuclear cell (MNC) isolation
for flow cytometric analysis and functional assays were ob-
tained from 15 patients with AS, 15 patients with CD, and 15
healthy subjects. Written informed consent was obtained from
all subjects, and the study protocol was approved by the local
ethics committee of the University of Palermo.
Histomorphologic grading, goblet cell count, and eval-
uation of mucin content. Tissue samples were processed as
previously described (1), and the degree of inflammation was
evaluated by an experienced pathologist (AR). Specimens
from patients with AS were divided into the following 3
subgroups, as previously described (1): those with normal gut
histology, those with acute inflammation, and those with
chronic inflammation. Briefly, acute inflammation was defined
by the preservation of normal architecture, with the presence
of neutrophils and/or eosinophils in the crypt and villus
epithelium. Chronic inflammation was defined by alterations
of the mucosal architecture, with villous blunting and fusion in
the ileal mucosa and an active granulocytic infiltrate in the
epithelium accompanied by an increased MNC infiltrate and
formation of basal lymphoid aggregates in the lamina propria.
After standard hematoxylin and eosin staining, goblet cells
were counted in sections from patients and controls. The
number of goblet cells was assessed by counting the vacuoles in
"3 crypts per slide. The number of goblet cells was normalized
to the total number of epithelial cells (obtained by counting the
nuclei) in the same crypt. Periodic acid–Schiff (PAS) and
Alcian blue staining was used for the evaluation of intraepi-
thelial mucin content.
Culture media, reagents, and antibodies. In all of the
in vitro assays, cells were maintained in very low endotoxin
RPMI 1640 medium (Sigma), 10 mM HEPES (EuroClone),
10% fetal bovine serum (EuroClone), 100 units/ml penicillin/
streptomycin, and 0.05 mM 2-mercaptoethanol (Sigma). Phos-
phate buffered saline was obtained from EuroClone.
The following antibodies were used for flow cytometric
analysis: goat anti-human IL-22 (R&D Systems), fluorescein
isothiocyanate (FITC)–conjugated anti-goat IgG (Becton
Dickinson), phycoerythrin (PE)–conjugated mouse anti-
human CD4 (Becton Dickinson), allophycocyanin (APC)–
conjugated anti-human IL-17 (R&D Systems), PE-conjugated
anti-human IFN! (Becton Dickinson), PE-conjugated mouse
anti-human NKp44, FITC-conjugated mouse anti-human
NKp46 (BioLegend), APC-conjugated mouse anti-human
CD3 (Becton Dickinson), and PerCP-conjugated mouse anti-
human CD56 (Becton Dickinson). Isotype-matched irrelevant
antibodies were used as a negative control.
Isolation of lamina propria MNCs. Lamina propria
MNCs were isolated from the gut biopsy specimens of 15
Figure 1. Increased frequency of CD3$CD56!NKp44!NKp46$ cells in isolated lamina propria mononuclear cells (MNCs) from patients with
ankylosing spondylitis (AS). Freshly isolated lamina propria MNCs from 15 patients with AS, 15 patients with Crohn’s disease (CD), and 15 normal
controls (NCs) were analyzed by flow cytometry. A, Representative dot plot of NKp44-expressing versus CD56-expressing cells among lamina
propria MNCs from patients and controls (left) and percentages of CD3$CD56!NKp44!NKp46$ cells among isolated lamina propria MNCs from
patients and controls (right). ! " P # 0.05 versus all other groups. B, Representative dot plot of NKp46-expressing versus CD56-expressing cells
among lamina propria MNCs from patients and controls. C, Percentages of CD3$CD56!NKp44$NKp46! cells among lamina propria MNCs from
patients and controls. ! " P # 0.05 versus all other groups. D, Percentages of interferon-! (IFN!)–producing CD3$CD56!NKp44$NKp46! cells
among lamina propria MNCs from patients and controls. P # 0.001, CD versus AS acute; P # 0.05, CD versus AS chronic; P # 0.001, CD versus
normal controls. In A, C, and D, symbols represent individual patients, horizontal lines represent the median, and whiskers represent the range. NS"
not significant. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
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patients with AS, 15 patients with CD, and 15 healthy controls,
as previously described (2). The isolated cells were counted
and checked for viability using 0.1% trypan blue (viability
ranged from 90% to 94%). Lamina propria MNCs were gated
on a lymphocyte gate based on forward and side scatter
patterns.
Flow cytometric analysis. Cell surface fluorescence
intensity was assessed using a FACSCalibur analyzer and
CellQuest software (Becton Dickinson). For analysis of intra-
cellular IL-17, IL-22, and IFN! production, cells were stimu-
lated with 1 #g/ml phorbol myristate acetate, 0.5 #g/ml iono-
mycin, and 10 #g/ml brefeldin A (all from Sigma-Aldrich) for
4 hours. Intracellular staining was performed using Cytofix/
Cytoperm reagent (Becton Dickinson) followed by goat anti-
human IL-22, APC-conjugated anti-human IL-17, and PE-
conjugated anti-human IFN! antibodies.
RNA extraction and quantitative TaqMan RT-PCR of
ileal biopsy specimens for IL-17, IL-22, IL-23, IL-17, STAT-3,
and MUC-1. Quantitative real-time PCR analysis of target
gene expression in the intestinal biopsy samples was performed
as previously described (1,2). For quantitative TaqMan real-
time PCR, Master Mix and TaqMan gene expression assays for
GAPDH control and for IL-22 (Hs01574154_m1), IL-23
(Hs00372324_m1), IL-17 (Hs00174383_m1), STAT-3
(Hs00234174_m1), and mucin 1 (MUC-1; Hs00904324_m1)
were obtained from Applied Biosystems. Samples were run in
triplicate using the One-Step real-time PCR system (Applied
Biosystems). Relative changes in gene expression between
control and inflamed ileal samples were determined using the
%%Ct method. Levels of the target transcript were normalized
to a GAPDH endogenous control, expressed as a constant
(%Ct) in both groups. For %%Ct values, additional subtractions
were performed between %Ct values for ileal samples from
patients and those from controls. Final values were expressed
as the fold induction.
Immunohistochemical analysis for NKp44, IL-22, and
pSTAT-3. Immunohistochemical analysis for NKp44, IL-22,
and pSTAT-3 was performed on 5-#m–thick paraffin-
embedded intestinal biopsy sections and lymph node sections
(used as positive controls) from patients and controls, as
previously described (1). The primary antibodies, rabbit anti-
human NKp44 (1:100 dilution; BioLegend), rabbit anti-human
IL-22 (IgG, NB100-737; 1:100 dilution) (Novus Biologicals),
and phosphorylated rabbit monoclonal anti-human pSTAT-3
(Tyr705) (IgG, D3A7; 1:50 dilution) (Cell Signaling Technol-
ogy), were added and incubated for 1 hour at room tempera-
ture. Ileal and lymph node sections incubated with an isotype-
matched control antibody were used as a negative control. The
numbers of NKp44–, IL-22–, and pSTAT-3–expressing cells
were determined by counting the immunoreactive cells on
photomicrographs obtained from 3 random high-power micro-
scopic fields (original magnification & 400) under a Leica
DM2000 optical microscope using a Leica DFC320 digital
camera.
Statistical analysis. Statistical analysis was performed
using the Kruskal-Wallis nonparametric test, with Dunn’s post
hoc test. Pearson’s correlation was used to quantify the expres-
sion associations between the genes of interest. P values less
than 0.05 were considered significant. All data are expressed as
the median (range).
RESULTS
Histomorphologic grading. On the basis of gut
histology as defined above and as previously described
(1), we identified 2 main groups of AS patients: patients
displaying normal histology or minor inflammatory signs
(acute lesions) (n " 8) and patients with chronic inflam-
mation (n " 7). As shown in Table 1, the 2 groups of AS
patients did not significantly differ with regard to demo-
graphic characteristics, clinical presentation, or medica-
tions received.
Expansion of CD3"CD56!NKp44!NKp46"
NK cells in the inflamed ileum of AS patients. Two
distinct populations of intestinal NK cells,
CD3$CD56!NKp44!NKp46$ and CD3$CD56!
NKp44$NKp46!, classified on the basis of NKp44 and
NKp46 surface expression, were observed. The propor-
tion of CD3$CD56!NKp44!NKp46$ cells was signif-
icantly increased in AS patients compared to CD pa-
tients and normal controls (Figure 1A), while the
proportion of CD3$CD56!NKp44$NKp46! cells was
significantly increased in CD patients compared to AS
patients and normal controls (Figures 1B andC). CD56!
NKp44!NKp46$ and CD56!NKp44$NKp46! cell
numbers were balanced in the ileal mucosa of normal
controls (Figures 1A–C). The increase in the numbers of
NKp44! cells in AS patients was confirmed by immu-
nohistochemical analysis performed on paraffin-
embedded ileal sections from patients and controls.
(Results are available from the author upon request.)
Even though CD3$CD56!NKp44$NKp46! cells were
not increased in AS, we next evaluated the percentage of
IFN!-producing NKp46! cells in all groups of subjects.
As shown in Figure 1D, the percentage of IFN!-
producing CD3$CD56!NKp44$NKp46! cells was
significantly increased in CD patients but not in AS
patients and controls. (Representative dot plots of iso-
type control antibodies are available from the author
upon request.)
CD56!NKp44!NKp46" NK cells are the main
source of IL-22 in the gut of AS patients. We next
evaluated the cellular source of IL-22 among isolated
lamina propria MNCs from AS patients. To date, the
best-characterized human mucosal cells that secrete
IL-22 are known to be CD4!IL-22–expressing T cells
(Th1, Th17, and Th22) and NKp44! NK cells (for
review, see ref. 18). Different results were observed in
the groups studied. CD3$CD56! cells coexpressing
NKp44 were the main producers of IL-22 in AS patients
with chronic intestinal inflammation (median 3% [range
3–4%]), compared to AS patients with acute inflamma-
tion (median 1.3% [range 0.88–1.7%]), CD patients
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(median 0.8% [range 0.55–1.2%]), and normal controls
(median 0.9% [range 0.4–1.2%]) (P # 0.05, AS patients
with chronic inflammation versus all other groups) (Fig-
ure 2A). Conversely, CD4! T lymphocytes were the
main source of IL-22 in CD patients (median 4.1%
[range 3–7%]), compared to AS patients with chronic
inflammation (median 2% [range 1.3–3%]), AS patients
with acute inflammation (median 1.05% [range 0.66–
1.2%]), and normal controls (median 1.1% [range 0.7–
3%]) (P # 0.05, CD patients versus all other groups)
(Figure 2B). Among CD4! T cells, the percentage of
IL-22–producing Th1, Th17, and Th22 cells was not
significantly increased in AS patients, regardless of the
degree of intestinal inflammation, compared to controls
(Figures 2C–E). Conversely, the percentages of IL-22–
producing Th1, Th17, and Th22 cells were significantly
expanded in CD patients (Figures 2C–E).
Overexpression of IL-22 mRNA in the inflamed
ileum of AS patients. The results described above
strongly suggest that IL-22–producing CD3$
CD56!NKp44!NKp46$ NK cells are enriched and
represent the main cellular source of IL-22 in the
inflamed ileum of AS patients. We next assessed the
expression of IL-22, IL-23, STAT-3, and MUC-1 mRNA
in the inflamed ileum of AS patients, CD patients, and
controls.
As previously described (1), IL-23 levels, but not
IL-17 levels, were significantly increased in AS patients
(data not shown). Because IL-22 has been demonstrated
to be produced when IL-23 is stimulated, we next
evaluated the expression of IL-22. As shown in Figure
3A, IL-22 was significantly overexpressed in the in-
flamed ileum of patients with chronic AS and patients
with CD compared to patients with acute AS and
controls. IL-22 levels were '40-fold and '50-fold
higher in patients with chronic AS and patients with CD,
respectively, than in controls.
Intestinal epithelial STAT-3 activation has been
demonstrated to regulate immune homeostasis in the
gut by promoting IL-22–dependent mucosal wound
healing (19). Consistent with IL-22 up-regulation,
STAT-3 was significantly increased in AS patients, to
Figure 2. Interleukin-22 (IL-22)–producing cells in the gut of patients and controls. Freshly isolated lamina propria MNCs from 15 patients with
AS, 15 patients with CD, and 15 healthy subjects were analyzed by flow cytometry. A, Representative dot plot of IL-22–expressing versus
NKp44-expressing cells among lamina propria MNCs from patients and controls (left) and percentages of NKp44!IL-22! cells among isolated
lamina propria MNCs from patients and controls (right). ! " P # 0.05 versus all other groups. B, Percentages of CD4!IL-22! cells among isolated
lamina propria MNCs from patients and controls (left) and representative dot plot of IL-22–expressing versus CD4-expressing cells among lamina
propria MNCs from patients and controls (right). ! " P # 0.05 versus all other groups. C–E, Percentages of different subsets of IL-22–producing
Th1 (C), Th17 (D), and Th22 (E) cells among lamina propria MNCs from patients and controls. In C and D, P # 0.0001, CD versus AS acute; P #
0.01, CD versus normal controls. In E, ! " P # 0.05 versus all other groups. Symbols represent individual patients, horizontal lines represent the
median, and whiskers represent the range. See Figure 1 for other definitions. Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
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levels similar to those observed in CD patients (data not
shown).
Because IL-22 has been demonstrated to induce
tissue-protective responses through the production of
mucins by intestinal epithelial cells (10), we also evalu-
ated the expression of MUC-1 mRNA. As shown in
Figure 4. Immunohistochemical analysis of interleukin-22 (IL-22) expression in ileal samples from patients and controls. Five-micrometer–thick
paraffin-embedded sections of ileal biopsy specimens obtained from patients and controls were treated with isotype control or anti–IL-22 antibodies.
A–D, Staining for IL-22 in specimens from a normal control (A), an AS patient with acute inflammation (B), an AS patient with chronic inflammation
(C), and a CD patient (D). IL-22–positive cells were rarely observed in normal controls and in AS patients with acute inflammation. Significant
staining for IL-22 was observed only in AS patients with chronic inflammation and CD patients. Positively stained cells were observed among
infiltrating MNCs and epithelial cells. Original magnification & 250. E, An ileal biopsy specimen from a CD patient, treated with isotype control
antibody. Original magnification& 250. F, Quantification of IL-22! cells in ileal biopsy specimens from patients and controls. Results are expressed
as the number of positive cells per field. Symbols represent individual patients, horizontal lines represent the median, and whiskers represent the
range. P # 0.05, AS acute versus AS chronic; P # 0.01, AS acute versus CD; P # 0.01, AS chronic versus normal controls; P # 0.001, CD versus
normal controls. See Figure 1 for other definitions.
Figure 3. Interleukin-22 (IL-22) and mucin 1 (MUC-1) gene expression profiles in mucosal biopsy specimens from AS patients, CD patients, and
normal controls. A, Relative mRNA quantification of IL-22, assessed by quantitative reverse transcriptase–polymerase chain reaction (RT-PCR), in
ileal biopsy specimens. P # 0.05, AS chronic versus AS acute; P # 0.05, AS chronic versus normal controls; P # 0.0001, CD versus AS acute; P #
0.0001, CD versus normal controls. B, Relative mRNA quantification of MUC-1, assessed by quantitative RT-PCR, in ileal biopsy specimens. ! "
P # 0.0001 versus all other groups. Symbols represent individual patients, horizontal lines represent the median, and whiskers represent the range.
See Figure 1 for other definitions.
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Figure 3B, MUC-1 expression was increased (8 fold)
in AS patients with chronic inflammation compared
to controls. MUC-1 mRNA expression was decreased
in the involved ileal mucosa of patients with Crohn’s
disease when compared to controls. The difference,
however, was not significant and was presumably the
result of loss of epithelial integrity due to inflammatory
processes.
IL-22 and pSTAT-3 expression in ileal specimens
from patients with AS with chronic inflammation.Given
the strong up-regulation of IL-22 mRNA in mucosal
biopsy specimens from patients with AS and patients
with CD, we next investigated its protein expression.
IL-22–positive cells were rarely observed in normal
controls (Figure 4A) or AS patients with acute inflam-
mation (Figure 4B). Immunohistochemical analysis of
all inflamed specimens from AS patients and CD pa-
tients showed a higher expression of IL-22 in AS patients
with chronic inflammation (Figure 4C) and patients
with CD (Figure 4D), confirming the up-regulation of
IL-22 mRNA observed in the RT-PCR assay. Cells
with positive staining were observed among MNCs dis-
tributed within the lymphomonocytic inflammatory in-
filtrates and epithelial cells (Figures 4C and D). Termi-
nal ileal biopsy specimens from AS patients with chronic
inflammatory lesions and from CD patients showed the
highest fraction of IL-22–expressing cells, which was
significantly higher than that in controls (Figure 4F).
Both IL-23 and IL-22 signal through STAT-3 in
different cellular targets, the former mainly in lymphoid
cells and the latter mainly in epithelial cells. To assess
whether IL-22 and IL-23 signals were active, we looked
for the activation of the downstream signaling pathway
by evaluating STAT-3 expression. Since the function of
STAT molecules is not reflected by transcript levels but
rather by their phosphorylation status, we next investi-
gated pSTAT-3 protein expression in ileal specimens
from patients and controls. As shown in Figure 5B,
pSTAT-3–expressing cells were rarely detected in nor-
mal controls. Immunohistochemical analysis of samples
from AS patients and CD patients demonstrated 2
different patterns of pSTAT-3 expression. The first
pattern, prominent in CD patients, was characterized by
a large number of pSTAT-3–expressing cells within the
lymphomonocytic inflammatory infiltrates (Figure 5C).
The second pattern of pSTAT-3 expression, character-
ized by abundant epithelial expression of pSTAT-3, was
detected in the terminal ileum of both CD and AS
Figure 5. Immunohistochemical analysis of pSTAT-3 expression in ileal samples from patients and controls. Five-micrometer–thick paraffin-
embedded sections of ileal biopsy specimens obtained from patients and controls were treated with isotype control or pSTAT-3 antibodies. A, An
ileal biopsy specimen from a CD patient, treated with isotype control antibody. Original magnification & 250. B–E, Staining for pSTAT-3 in
specimens from a normal control (B), a CD patient (C), an AS patient with acute inflammation (D), and an AS patient with chronic inflammation
(E). Epithelial cells positive for pSTAT-3 were rarely observed in normal controls. Abundant pSTAT-3! infiltrating inflammatory cells were
observed in CD patients. CD patients, AS patients with acute inflammation, and AS patients with chronic inflammation showed intense epithelial
pSTAT-3 positivity. Original magnification & 250. F and G, Quantification of pSTAT-3! cells among infiltrating cells (F) and epithelial cells (G)
in ileal biopsy specimens from patients and controls. Results are expressed as the number of positive cells per field. Symbols represent individual
patients, horizontal lines represent the median, and whiskers represent the range. In F, P# 0.01, AS chronic AS acute; P# 0.001, AS chronic versus
CD; P # 0.05, AS chronic versus normal controls; P # 0.0001, CD versus normal controls. In G, P # 0.01, AS chronic versus AS acute; P # 0.0001,
AS chronic versus normal controls; P # 0.05 CD versus AS acute; P # 0.0001, CD versus normal controls. See Figure 1 for other definitions. Color
figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
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patients irrespective of the presence or absence of
inflammatory lesions (Figures 5C–E).
We then compared the numbers of pSTAT-3–
positive cells in samples from AS patients, CD patients,
and normal controls. As shown in Figures 5F and G,
terminal ileal biopsy specimens from AS patients with
chronic inflammatory lesions and CD patients showed
the highest fraction of pSTAT-3–expressing cells among
infiltrating cells (median 26% [range 17–28%] and 34%
[range 18–56%], respectively) and epithelial cells (me-
dian 33% [range 27–46%] and 26% [range 12–35%],
respectively) compared to controls (median 4% [range
2–6%] in infiltrating cells and 11% [range 6–14%] in
epithelial cells). In AS patients with acute inflammation,
pSTAT-3 expression in infiltrating cells (median 6%
[range 4–8%]) and epithelial cells (median 12% [range
11–17%]) was not significantly different from that in
controls.
Interestingly, in AS patients with chronic inflam-
mation but not in CD patients, the number of IL-22!
cells was significantly correlated with the number of
pSTAT-3–positive epithelial cells. (Results are available
from the author upon request.) This suggests a promi-
nent role of pSTAT-3 in mediating IL-22 signaling at
this site in AS patients.
Goblet cell count and evaluation of mucin con-
tent in subclinical gut inflammation in AS patients. In
experimental models of intestinal inflammation, IL-22
enhances STAT-3 activation specifically within colonic
epithelial cells and induces both STAT-3–dependent
expression of mucus-associated molecules and restitu-
tion of mucus-producing goblet cells (10). In this regard,
we next considered the frequency of mucin-producing
goblet cells and the mucin content in the ileum of
patients and controls.
Specimens from AS patients with chronic inflam-
mation showed an increased percentage of goblet cells
(64%) compared to controls (47%) (P # 0.05) (Figures
6A, B, and D). A significantly reduced percentage of
goblet cells was observed in CD patients (23%; P #
0.001 versus controls), probably due to the inflammatory
process–related loss of epithelial integrity (Figures 6C
and D).
A strong Alcian blue PAS-positive reaction was
seen in AS patients compared to controls and CD
patients (Figures 6A–C).
DISCUSSION
This is the first study to show that NKp44! NK
cells are increased in the gut mucosa of patients with AS
exhibiting subclinical chronic intestinal inflammation.
We also demonstrate that IL-22 is overexpressed in
the ileum of AS patients, and that NKp44! NK cells
represent its major source. Finally, increased IL-22
expression is accompanied by goblet cell hyperplasia and
increased mucus production, suggesting that it plays a
tissue-protective rather than a proinflammatory role in
AS.
Natural killer cells are innate lymphocytes in-
volved in innate and adaptive immune responses. Al-
though classified into 2 main subsets on the basis of the
level of expression of the adhesion molecule CD56, NK
cells have long been considered to be a homogeneous
population with stereotyped roles in immune responses.
Recently, several studies have demonstrated significant
diversification of NK cell function in the intestinal
mucosa (4–8), identifying a rare mucosal NK cell sub-
population expressing the nuclear transcription factor
retinoic acid receptor–related orphan nuclear receptor
(ROR!t) (which is not expressed by classic NK cells)
and the surface marker NKp44 (which is expressed by
Figure 6. Mucin content and number of goblet cells in ileal samples
from patients and controls. A–C, Representative photomicrographs
showing 5-#m–thick paraffin-embedded sections of ileal biopsy spec-
imens obtained from a normal control (A), an AS patient (B), and a
CD patient (C), stained with periodic acid–Schiff and Alcian blue for
evaluation of mucin content. Increased mucin content and increased
numbers of mucin-positive epithelial cells were observed in AS pa-
tients compared to healthy controls and CD patients. Original magni-
fication & 100. D, Number of goblet cells in the mucosa. Results
are expressed as the number of positive cells per field. Symbols
represent individual patients, horizontal lines represent the median,
and whiskers represent the range. P # 0.0001, AS chronic versus
CD; P # 0.0001, AS acute versus CD; P # 0.05, AS chronic versus
normal controls; P # 0.001, CD versus normal controls. See Figure 1
for other definitions. Color figure can be viewed in the online issue,
which is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
1529-0131.
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activated classic NK cells). Although the nature of
NKp44! non-T cells and their relationship with classic
NK cells is currently a subject of controversy, lamina
propria NK cells have been classified, on the basis of the
expression of the 2 natural cytotoxic receptors NKp44
and NKp46, into 2 main subsets, NKp44! and NKp46!
NK cells, which are balanced in normal human intestinal
mucosa (9). Although NKp44! and NKp46! NK cells
seem to play divergent roles in the gut, the former being
essentially protective through the release of IL-22, and
the latter being essentially pathogenic through the pro-
duction of IFN!, both are controlled by IL-23 signaling
(4,9).
IL-22 is a member of the IL-10 family of cyto-
kines (for review, see ref. 18). The direct effects of IL-22
are restricted to nonhematopoietic cells, since its recep-
tor is expressed on the surface of epithelial cells and
some fibroblasts in various organs, including parenchy-
mal tissue of the gut, lung, skin, and liver. All studies
investigating IL-22–induced signal transduction in cells
with endogenous receptor expression demonstrated ty-
rosine phosphorylation of STAT-3 (4,19–22).
Although IL-22 has been demonstrated to ame-
liorate intestinal inflammation through the induction of
mucin expression and the restitution of goblet cells
during recovery from acute intestinal injury in a mouse
model of ulcerative colitis (10), the exact role of IL-22,
whether protective or inflammatory, in human inflam-
matory bowel disease is still poorly understood. Al-
though it is likely that the pathogenic effect of IL-22
could reflect dysregulated duration of production and/or
the concentration of IL-22, the functional outcomes of
IL-22 expression seem to be governed by coexpression of
IL-17A. When coexpressed, IL-17A and IL-22 act syn-
ergistically to promote chemokine expression, neutro-
phil recruitment, and inflammation, whereas IL-22 in
the absence of IL-17A promotes essentially tissue-
protective responses (16).
In the present study, IL-22 expression, as dem-
onstrated by both RT-PCR and immunohistochemistry,
was more pronounced in AS patients with chronic
intestinal inflammation and CD patients and was accom-
panied by increased IL-23 but not IL-17 levels in AS
patients. Intense positive staining for IL-22 was observed
among the MNCs infiltrating the inflamed ileal biopsy
specimens of both AS patients and CD patients. Al-
though it is arduous to immunohistochemically distin-
guish between surface staining and intracellular staining,
we also observed strong staining for IL-22 in the epithe-
lium, which we believe is produced by epithelial cells.
Indeed, expression of IL-22 has recently been reported
in epithelial cells from the salivary glands of patients
with Sjo¨gren’s syndrome (23).
Interestingly, in AS patient samples, IL-22 ex-
pression at the protein level was significantly correlated
with the increased epithelial expression of pSTAT-3.
The absence of concomitant IL-17 expression, taken
together with STAT-3 mRNA overexpression and the
observation that the active phosphorylated form of
STAT-3 resides almost exclusively in the epithelial cells
of the ileum of AS patients, could suggest a prevalent
role of pSTAT-3 in regulating immune homeostasis in
the gut by promoting IL-22–dependent mucosal wound
healing. In this regard, expansion of IL-22–producing
NKp44! cells in AS patients was associated with in-
creased MUC-1 transcript levels and an increased num-
ber of mucin-producing goblet cells, supporting the
notion of a protective phenotype in the ileum of AS
patients.
This study suggests that intestinal overexpression
of IL-23 in AS patients could be oriented toward a
protective rather than a pathogenic role in intestinal
inflammation. IL-23 overexpression could play a central
role in modulating IL-22 production in NKp44!IL-22!
cells, generating an intestinal milieu rich in STAT-3,
which favors the expression of ROR!t in lymphoid cells
of the lamina propria (24), the expression of IL-22, and,
under certain conditions (such as the concomitant pres-
ence of proinflammatory cytokines), the expression of
IL-17.
In conclusion, this is the first study to demon-
strate that IL-22!NKp44! NK cells are significantly
expanded in the inflamed ileum of AS patients. Differ-
ential temporal and spatial coexpression of IL-22 and
IL-17 may determine the balance between the protective
and proinflammatory roles of IL-22 in the intestinal
mucosa in AS patients and the eventual evolution to-
ward overt Crohn’s disease. The factors conditioning this
evolution remain to be elucidated.
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